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Interleukin-1b (IL-1b) and its endogenous antagonist, the interleukin-1 receptor antagonist (IL-1ra), play
important roles in immune responses. In sarcoidosis, IL-1b is reported to be increased whereas IL-1ra is decreased.
It has recently been shown that polymorphisms in the IL-1ra and IL-1b genes may account for variation in the two
proteins. These polymorphisms are also reported to be associated with several autoimmune diseases. Since this
might be expected to affect sarcoidosis, an investigation of 108 sarcoidosis patients and 113 healthy control subjects
was performed.
The IL-1ra genotype was determined using the polymerase chain reaction (PCR), and the IL-1b genotype by
PCR restriction fragment length polymorphism.
We found no significant differences in IL-ra and IL-1b genotypes between sarcoidosis patients and healthy
controls. Furthermore, there was no association between the IL-1b genotype and the roentgenographic stage,
disappearance of chest X-ray shadows or organ involvement.
In conclusion, there is no bias in the IL-1ra and IL-1b genotype in Japanese sarcoidosis patients.
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Interleukin-1b (IL-1b) has been reported as an important
mediator of the immune response. Previous study has
shown that it activates lymphocytes and induces production
of several cytokines by immune cells in the lung, including
interleukin-6, interleukin-8, tumour necrosis factor-alpha
(TNFa) and monocyte chemoattractant peptide 1. An
endogenous antagonist, interleukin-1 receptor antagonist
(IL-1ra), was isolated that inhibits IL-1b bioactivity
competitive binding to the IL-1b receptor, thus suppressing
the IL-1b induction of cytokines. Both IL-1b and IL-1ra
may play important roles in inflammatory reactions (1–4).
The gene for IL-1b is located on the long arm of human
chromosome 2, in close linkage with another gene of the IL-
1 gene family, that encoding IL-1ra. Polymorphisms have
recently been described for both IL-1ra and IL-1b (4–6).
The polymorphism in human IL-1ra gene intron 2 is caused
by variable numbers of an 86-bp tandem repeat. Allele 2Received 20 July 1999 and accepted in revised form 18 May 2000.
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0954-6111/00/111038+05 $35?00/0was reported to be associated with enhanced production of
IL-1ra (4,7,8) and IL-1b proteins (4,9). Within the IL-1b
gene, a Taq I restriction fragment length polymorphism in
exon 5 has also been reported to influence the production of
IL-1b protein. The allele 2 represents an IL-1b high-
secretor phenotype (4,6).
Recently, the IL-1ra gene allele 2 was reported to be
associated with inflammatory bowel disease (4,10,11),
multiple sclerosis (4,12), systemic lupus erythematosis
(4,13), lichen sclerosis (4,14) and Sjo˜gren’s syndrome
(15). With regard to the IL-1b gene polymorphism,
some investigators have found allele 2 to be linked to
myasthenia gravis (4,16) and insulin-dependent diabetes
mellitus (4,6).
Sarcoidosis is a systematic granulomatous disorder of
unknown aetiology. Previous investigations demonstrated
that IL-1ra and IL-1b both play a role in the immune
response of sarcoidosis patients: IL-1b production by
alveolar macrophages being increased and generation of
IL-1ra decreased (17,18). IL-1b and IL-1ra may function as
immunomodulators of sarcoid granulomas, so that allelic
variation of IL-1b and IL-1ra gene might be expected to
have an impact on the disease. Since this has so far not
received attention to our knowledge, the present study was
conducted with the aim of ascertaining whether IL-1b and
IL-1ra might affect sarcoidosis.# 2000 HARCOURT PUBLISHERS LTD
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SUBJECTS
The 108 sarcoidosis patients (88 females and 20 males)
studied were all inhabitants of central Japan. Sarcoidosis
was diagnosed based on the clinical picture and the
presence of epithelioid cell granulomas in biopsy specimens
from lung, skin or lymph nodes. They had a mean age of
55?7+15?1 (mean+SD) years. All but 14 had chest
roentgenologic evidence of sarcoidosis, 78 with stage I, 11
with stage II and five with stage III disease.
As healthy controls, 113 unrelated healthy subjects (58
females and 55 males) living in the same area of Japan were
selected. They had a mean age of 40?0+11?8 years with no
past history of pulmonary disease or any abnormalities on
physical examination, chest radiography, ECG, urinalysis
and routine laboratory blood testing. None of the controls
was receiving medication at the time of the evaluation.
Informed consent was obtained from all patients and
healthy controls.
DETERMINATION OF IL-1ra GENOTYPES
DNA was extracted from peripheral leukocytes with
standard techniques. Specific oligonucleotide primers 5’-
CTCAGCAACACTCCTAT-3’ and 5’-TCCTGGTCTGCA
GGTAA-3’ were utilized in PCR to amplify a fragment of
the IL-1ra gene, with denaturation at 948C for 1min,
followed by 35 cycles at 948C for 1min, 608C for 1min and
708C for 1?5min and a final extension at 728C for 5min
(DNA Thermal Cycler 2400, Perkin Elmer-Cetus, Norwalk,
CT, U.S.A.). PCR products were analysed on 2% ethidium
bromide agarose gels. In the second intron of this gene five
alleles are defined by different numbers of a 86-bp segmentFIG. 1. Interleukin-1 receptor antagonist genotypes
obtained in this study. Panel shows a representative 2%
agarose gel stained with ethidium bromide and
photographed under ultraviolet transillumination after
PCR amplification. The bands show allele 3 (500 bp),
allele 1 (410 bp), allele 4 (325 bp) and allele 2 (240 bp).
Four genotypes, A1A1, A1A3, A1A4 and A2A2 are
evident. Allele 5 (595 bp) was not found in this study. The
left lane contains markers.repeat. Genotypes were determined by comparing the size
of the bands with a molecular weight ladder, with
separation into 410 bp (allele 1), 240 bp (allele 2), 500 bp
(allele 3), 325 bp (allele 4) and 595 bp (allele 5) (Fig. 1).
DETERMINATION OF IL-1b GENOTYPES
The region containing the IL-1b polymorphic site was
amplified with the primers 5’-GTTGTCATCAGACTTT-
GACC-3’ and 5’-TTCAGTTCATATGGACCAGA-3’. The
PCR conditions were 958C for 5min, followed by five cycles
at 958C for 1min, 518C for 1min and 748C for 1min, then
30 cycles at 958C for 0?5min, 518C for 0?5min and 748C for
0?5min. The final extension was carried out at 748C for
10min. Aliquots of the PCR products was analysed on 2%
agarose gels stained with ethidium bromide before digestion
to control for correct amplification. Taq I digestion (1 unit)
of the 249 bp fragments at 658C for 90min resulted in
fragments that either remained intact or were cut in two
fragments of 135 bp and 114 bp, respectively. The samples
were then analysed by electrophoresis on a 3% agalose gel
stained with ethidium bromide and the genotypes were
determined. The allele with a recognition sequence for the
Taq I has been named allele 1, and the other, which is not
cut by Taq I, allele 2. There are three genotypes, homo-
zygous for the digestive allele A2A2, homozygous for
undigestive allele A1A1 and heterozygous for A1A2 (Fig. 2).
STATISTICAL ANALYSIS
The allele ratio and genotype distribution of sarcoidosis
patients and healthy control subjects, and clinical manifes-
tation of the disease among the genotypes were analysed
with the Fisher’s exact test. A P-value 5 0?05 was
considered significant.FIG. 2. Determination of interleukin-1b genotypes. Panel
shows a representative 3% agarose gel stained with
ethidium bromide after PCR amplification and digestion
by Taq I. The upper single band is the allele 2 fragment
(249 bp) and the lower double bands are allele 1 fragments
(135 bp and 114 bp). The A1A1 type and the A1A2 type
are shown. We found no A2A2 type in this study. The left
lane contains markers.
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IL-1ra GENOTYPE DISTRIBUTION
Of the 113 healthy control subjects, 111 had the A1A1
genotype, one the A1A3 genotype and one the A1A4
genotype. Of the 108 sarcoidosis patients, 105 had the
A1A1 genotype, two had A1A3 and one had A2A2. Since
there were few subjects other than A1A1 type we grouped
other genotypes together for comparison. When we
compared A1A1 with other types, we found no difference
in IL-1ra genotype distribution between healthy subjects
and sarcoidosis patients (Table 1).
IL-1b GENOTYPE DISTRIBUTION
Of the 113 healthy control subjects, 104 had the A1A1
genotype and nine the A1A2 type; no A2A2 type
individuals were included. The A1 allele/A2 allele ratio
was 0?960/0?040. Of the 108 sarcoidosis patients, 94 were
A1A1 type, 14 were A1A2 and none were A2A2. The A1/
A2 allele ratio was 0?935/0?065. There was no significant
difference in the genotype distribution between healthy
controls and sarcoidosis patients, and no variation in the
frequency of the allele was observed (Table 1).
GENOTYPES AND CLINICAL
CHARACTERISTICS OF DISEASE
Since genotypes other than A1A1 were very rare, it was
dicult to examine any subgroup analysis of IL-1ra
genotypes. Therefore we investigated the correlation
between only the IL-1b genotype and clinical characteristics
of sarcoidosis patients. Firstly, we examined IL-1b geno-
type distributions among the three roentgenographic stages
of sarcoidosis patients. Of 94 subjects with roentgeno-
graphic findings, 80 were of A1A1 type: 66 in stage I, nine
in stage II and five in stage III, while 14 were of A1A2 type:
12 stage I, two stage II and no stage III. There was no
significant correlation between roentgenographic stage and
the IL-1b genotype. We also examined the genotype
distribution with respect to disappearance of shadows on
chest radiography within 3 years. Of 108 sarcoidosis
patients, 79 were available for 3-year follow-up without
steroid therapy. In these cases, 69 cases were of A1A1 typeTABLE 1. Genotype distributions of control subjects and sarcoi
IL-1ra ge
A1A1 (%)
Healthy control subjects n¼113 111 (98?2)
Sarcoidosis patients n¼108 105 (97?2)
No significant differences in distributions in IL-1ra (P¼0?68) an
control subjects and sarcoidosis patients.with 14 disappearance cases, whereas 10 cases were of
A1A2 type with two disappearance cases. The relative rates
were not different. Cases of eye, skin, heart, and three or
more organ involvement were examined, but the results
again indicated no specific association with the genotype
(Table 2).
Discussion
Sarcoidosis patients show different production patterns of
cytokines compared with healthy subjects, with IL-1b being
increased and IL-1ra decreased (17,18). Polymorphisms of
both the IL-1ra and IL-1b genes have been reported to
affect IL-1ra and IL-1b production (4). For example, allele
2 of IL-1ra and allele 2 of IL-1b are associated with
increased in-vitro production of IL-1b protein (4,6,9). The
IL-1ra allele 2 is also reported to be linked to elevated IL-
1ra plasma levels (4,7) or production by activated
peripheral blood mononuclear cells (4,8). The effect of the
IL-1ra allele 2 on plasma IL-1ra levels could only be seen in
persons who were also carriers of the IL-1b allele 2 (7).
Therefore, alleles with high agonist and high antagonist
generation might have enhanced homeostasis.
However, the present study did not demonstrate any
difference in distribution of either IL-1ra or IL-1b
genotypes between healthy control subjects and sarcoidosis
patients, or variation in IL-1b with clinical characteristics.
While IL-1ra allele 2 and IL-1b allele 2 have been reported
to confer risk of chronic inflammatory and autoimmune
disease (4,6,10–16), not all findings have been positive
(4,19–23). Thus, an association between these alleles and
disease has not been confirmed at the clinical level, in
agreement with our results.
Our Japanese healthy control group and sarcoidosis
patients contained few individuals with other than A1A1
type IL-1ra and A1A2 type IL-1b gene phenotypes, in
contrast with previous Caucasian studies (4–14,19–23) and
suggesting a racial bias. Even if the IL-1ra and IL-1b genes
do affect the production of IL-1ra and IL-1b, we speculate
the total influence might be weak and these alleles may not
represent a risk factor for Japanese sarcoidosis patients.
However, the small size of the population of high-
secretor allele carriers is a limitation of our study,
precluding firm conclusions. In comparison with healthy
control subjects, a slight increase of IL-1b A1A2 type wasdosis patients
notype IL-1b genotype
Others (%) A1A1 (%) A1A2 (%)
2 (1?8) 104 (92?0) 9 (8?0)
3 (2?8) 94 (87?0) 14 (13?0)
d IL-1b (P¼0?27) genotypes were observed between healthy
TABLE 2. IL-1b genotype and clinical characteristics of
disease
A1A1 (%) A1A2 (%)
Rentgenographic stage*
I n¼78 66 (84?6) 12 (15?4)
II n¼11 9 (81?8) 2 (18?2)
III n¼5 5 (100?0) –
Disappearance of shadow{
Disappearance n¼16 14 (87?5) 2 (12?5)
Without disappearance n¼63 55 (87?3) 8 (12?7)
Organ involvement
Eye{ n¼59 50 (84?7) 9 (15?3)
Skin} n¼23 22 (95?7) 1 (4?3)
Heartk n¼7 5 (71?4) 2 (28?6)
More than three organs} n¼27 24 (88?9) 3 (11?1)
No significant differences in genotype distributions were
observed with respect to clinical characteristics.
*P¼0?86; {P¼1?00; {P¼0?57; }P¼0?29; kP¼0?22; }P¼1?00.
INTERLEUKIN 1 GENE POLYMORPHISMS IN SARCOIDOSIS 1041found (13% vs. 8%) and, while this was not significant,
further investigation of IL-ra and IL-1b gene polymorph-
isms in a larger series of sarcoidosis patients appears
warranted, especially with Caucasians who are reported to
be more likely to carry IL-1ra allele 2 or IL-1b allele 2.
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